TNGX - CIK 0001819133
Tango Therapeutics, Inc. trades as TNGX and has a market capitalization of $4.21 B, making it the #1527 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $62.38M, up 48.3% from the prior year and net income of -$101.60M. This page tracks Tango Therapeutics, Inc. through 382 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 5 fiscal years Tango Therapeutics, Inc.'s revenue grew from $7.66M to $62.38M, a compound annual growth rate of 52.1%. Net profit margin expanded from -678.8% to -162.9% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Major company event | 8-K | 2026-05-13 |
| Quarterly report | 10-Q | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-13 |
| SCHEDULE 13G/A | - | 2026-05-11 |
First clinical data from PRMT5/RAS(ON) combination trial to be pre sented in 2026
The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
Additional key appointments add expertise in clinical operations, corporate strategy and project leadership -
The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
The largest companies sharing Tango Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Tango Therapeutics, Inc. (TNGX) has a market capitalization of $4.21 B as of 2026-06-10, ranking #1527 among US-listed companies.
Tango Therapeutics, Inc. reported revenue of $62.38M for fiscal year 2025, an increase of 48.3% year over year.
In its latest fiscal year Tango Therapeutics, Inc. reported a net loss of $101.60M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
Initial Phase 1/2 trial data of vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors in MTAP-deleted pancreatic cancer in 2026 with continued robust patient enrollment